Saranac Partners’s Biogen BIIB Stock Holding History

Saranac Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-57	Closed	-$7.99K	–	88
2025 Q3	$7.99K	Buy	+57	New	+$7.71K	﹤0.01%	318

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Saranac Partners's BIIB Position: Q4 2025 in Review

Saranac Partners sold out of Biogen (BIIB) in Q4 2025, closing a stake of 57 shares — an estimated $7.99K sold.

Saranac Partners first reported a position in BIIB in Q3 2025 and held it in 1 quarter. The position peaked at $7.99K in Q3 2025. 999 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.

Saranac Partners reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
Saranac Partners sold 57 Biogen shares in Q4 2025, an estimated $7.99K.
Saranac Partners first reported a position in Biogen in Q3 2025 and held it in 1 quarter.
Saranac Partners's Biogen position peaked at $7.99K in Q3 2025.
999 funds tracked by Wall St. Rank held Biogen as of Q4 2025.

Based on Saranac Partners's 13F filing for Q4 2025, filed 6 Feb 2026.